Tag Archives: J&J

Outlook “Gloomy” for TB Investment

The approval last year of Johnson & Johnson’s (J&J) treatment for tuberculosis (bedaquiline) — at the time the first TB drug approval in 40 years — “remains an exception to the generally gloomy outlook” for investment in TB R&D, writes Andrew Ward in this week’s Financial Times.
Posted in Emerging Markets, Global, Strategy | Also tagged , , , , | Leave a comment

Frontrunners in Innovation: New Drug Approvals 2013

Frontrunners in Innovation: New Drug Approvals 2013 Trying to nail down the actual number of new drugs approvals in 2013 is like trying to swat a fly—it can be highly illusive.  Safe to say, however, as 2013 drew to a close,  the total number of new did not match 2012’s  high of 39. And yet, […]
Posted in Regulatory | Also tagged , , , , , | Leave a comment

ePharma Summit: Less Proselytizing, More Results

At the digital marketing-focused ePharma Summit in New York this week, many of the problems and frustrations related to the “big three” – Facebook, Twitter and YouTube – were hashed out for umpteenth time.
Posted in Advertising, E-Media, Events, Global, Marketing, patient education, Regulatory, social media, Strategy | Also tagged , , , | 1 Comment

Johnson & Johnson Slammed Over Manufacturing Practices, Phantom Recall

In 1982, Johnson & Johnson garnered an enduring amount of goodwill when, seemingly without any thought of lost profit, it immediately yanked Tylenol from the shelves nationwide after learning someone was slipping cyanide into bottles in Chicago. The company’s sure and swift PR response became the model for crisis management for the corporate world. But […]
Posted in Corporate Responsibility | Also tagged , , , , , , , , , | 3 Comments
  • Categories

  • Meta